PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·
← Leaderboard
RARE
Ticker

RARE

Congressional Trades
9
by 1 members
Buys
9
100%
Sells
0
0%
Total Volume
$72K
midpoint
Unique Traders
1
members

Party Breakdown

Democrats9 · 100%
Republicans0 · 0%

Party Trading Divergence

Democrat vs. Republican buy / sell pressure by monthHIGH DIVERGENCE

Bar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.

Democrat ←
Month
→ Republican
3
Jul '25
2
Aug '25
2
Feb '26
2
Mar '26
Democrats90Net buyers
vs
Republicans00Neutral
Net buyingNet selling⚡ Party split

💼 Lobbying Filings

all →
  • 2026-04-20$10K
    ULTRAGENYX PHARMACEUTICAL
    Issues related to drug development and market access.
  • 2026-04-20$0
    ULTRAGENYX PHARMACEUTICAL
    n/a termination report
  • 2026-04-20$0
    ULTRAGENYX PHARMACEUTICAL INC.
    Issues relating to rare disease and patient access.
  • 2026-04-17$440K
    ULTRAGENYX PHARMACEUTICAL INC.
    Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
  • 2026-04-17$60K
    ULTRAGENYX PHARMACEUTICAL INC.
    Issues relating to rare disease and patient access. H.R.1262/S. 932 - Give Kids a Chance Act of 2025. FY 2027 Appropriations.
  • 2026-04-17$0
    ULTRAGENYX PHARMACEUTICAL
    Issues related to drug development and market access.
  • 2026-03-30$0
    ULTRAGENYX PHARMACEUTICAL INC.
    Issues relating to rare disease and patient access.
  • 2026-01-16$130K
    ULTRAGENYX PHARMACEUTICAL INC.
    Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
  • 2026-01-16$60K
    ULTRAGENYX PHARMACEUTICAL INC.
    Issues relating to rare disease and patient access. H.R.1262/S. 932 - Give Kids a Chance Act of 2025.
  • 2026-01-15$38K
    ULTRAGENYX PHARMACEUTICAL
    - ultrarare disease - newborn screening - pediatric priority review voucher

Congressional Momentum

buy vs. sell pressureACCUMULATING

Score 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.

Last 30 Days
No trades
Last 90 Days
100
4 buys4 total0 sells
$32K buys · $0 sells
All-Time
100
9 buys9 total0 sells
$72K buys · $0 sells
Cumulative Net Position (buy vol − sell vol)
+$72K
2025-079 trades plotted2026-03

Trade Activity Timeline

Congressional buys & sells by month · last 4 months w/ activity

25/07
25/08
26/02
26/03
BuysSellsOtherHigh-volume month

All Disclosed Trades

DateMemberActionAmountFiling Delay
2026-03-03DGilbert CisnerosBUY$1K – $15K36d
2026-03-03DGilbert CisnerosBUY$1K – $15K35d
2026-02-18DGilbert CisnerosBUY$1K – $15K20d
2026-02-18DGilbert CisnerosBUY$1K – $15K19d
2025-08-08DGilbert CisnerosBUY$1K – $15K38d
2025-08-08DGilbert CisnerosBUY$1K – $15K35d
2025-07-15DGilbert CisnerosBUY$1K – $15K31d
2025-07-15DGilbert CisnerosBUY$1K – $15K30d
2025-07-15DGilbert CisnerosBUY$1K – $15K29d